Demand for GLP-1 therapies continues to grow, and additional entrants into the obesity and metabolic disease space are increasing the pressure even further
Four, 1 and 6 studies were categorized as having high risk, medium risk and unclear risk of detection bias, respectively
Subsequent clinical studies during the 2000s showed a glucose-lowering action of DPP-4 inhibitors also in human subjects with type 2 diabetes
5, 6, 8, 13, 14 This indicates that liraglutide treatment uncouples the increase in soluble leptin receptors that normally occurs during weight loss, thereby preventing the decrease in free leptin and thus preventing the increase in food-seeking behavior during weight loss maintenance
While oral supplements can be a way to replace B12, oral supplements dont always absorb in the digestive system